Miller Global Investments LLC Invests $875,000 in Pfizer Inc. $PFE

Miller Global Investments LLC purchased a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 35,145 shares of the biopharmaceutical company’s stock, valued at approximately $875,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer in the third quarter worth $29,000. Howard Hughes Medical Institute bought a new position in shares of Pfizer during the second quarter valued at $30,000. Darwin Wealth Management LLC bought a new position in shares of Pfizer during the second quarter valued at $32,000. Evelyn Partners Asset Management Ltd purchased a new position in shares of Pfizer in the 2nd quarter worth about $33,000. Finally, True Wealth Design LLC boosted its stake in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 TALAPRO‑3 topline: the TALZENNA (talazoparib) + XTANDI (enzalutamide) combo met the study’s primary endpoint with a significant improvement in radiographic progression‑free survival for HRR‑mutated metastatic castration‑sensitive prostate cancer — a potential label expansion and commercial upside for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Atirmociclib Phase II success: a second‑line metastatic breast cancer study met its primary endpoint, strengthening Pfizer’s mid‑stage oncology pipeline and adding incremental clinical value that could support future partnerships or asset monetization. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst upgrades and bullish forecasts: recent analyst upgrades and an HSBC note highlighting strong upside have coincided with intraday buying and headline momentum, supporting the stock’s short‑term lift. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Positive Sentiment: Income/safety narrative: coverage framing Pfizer as a defensive, dividend‑paying option amid macro and oil volatility is attracting yield‑focused investors. That narrative helps support multiple expansion versus more cyclical sectors. Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.
• Neutral Sentiment: Pfizer vs Moderna sector comparison pieces highlight differing growth drivers (vaccines vs diversified pharma/oncology) but are more background for positioning than immediate stock movers. Pfizer vs Moderna: Which Pharma Stock Has More Upside?
• Neutral Sentiment: Early‑stage study updates: Pfizer advanced a PF‑07328948 liver study (Phase 1) while also closing one early melanoma program — incremental pipeline news that fine‑tunes expectations but doesn’t materially alter the company’s overall revenue base today. Pfizer Advances Early PF-07328948 Liver Study, Adding Quiet Support to PFE’s Pipeline Story
• Negative Sentiment: Program termination: Pfizer ended an early‑stage melanoma study (PF‑08046031), which trims one oncology bet and highlights the usual R&D attrition risk that can temper optimism about pipeline breadth. Pfizer Ends Early-Stage Melanoma Study, Trimming One Oncology Bet But Not The Broader Pipeline

Analysts Set New Price Targets

Several analysts recently commented on PFE shares. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Citigroup assumed coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Finally, Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.14.

Pfizer Price Performance

Shares of PFE opened at $27.40 on Friday. The firm has a market cap of $155.78 billion, a PE ratio of 20.14 and a beta of 0.47. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm has a fifty day simple moving average of $26.65 and a two-hundred day simple moving average of $25.59. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the business posted $0.63 EPS. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.